Acyclovir Market

Executive Summary

Acyclovir Market was valued at US $2.40 billion in 2021 and is projected to grow at 4.18% CAGR over the forecast period to reach US $3.06 billion by 2027. Acyclovir Market represented US $0.19 billion opportunity over 2019-2021 and estimated to create US $0.67 billion opportunity in 2027 over 2021.

Acyclovir from Consainsights analyses the Acyclovir Market in the Life Sciences industry over the forecast period to 2027.

Acyclovir research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Acyclovir segmentation includes Type Of Virus, Mechanism Of Action, Application, Region and Geography.

Based on the Type Of Virus, the Acyclovir analysis covers HERPES SIMPLEX VIRUS TYPE I (HSV-1), HERPES SIMPLEX VIRUS TYPE II (HSV-2), VARICELLA ZOSTER VIRUS (VZV), EPSTEIN-BARR VIRUS (EBV), CYTOMEGALOVIRUS (CMV).

In Type Of Virus segment, HERPES SIMPLEX VIRUS TYPE I (HSV-1) segment has highest cagr growth of 3.71%.

Based on the Mechanism Of Action, the Acyclovir analysis covers NUCLEOTIDE POLYMERASE INHIBITORS, REVERSE TRANSCRIPTASE INHIBITORS, PROTEASE INHIBITORS, OTHERS.

In Mechanism Of Action segment, NUCLEOTIDE POLYMERASE INHIBITORS segment has highest cagr growth of 3.71%.

Based on the Application, the Acyclovir analysis covers HIV, HEPATITIS, HERPES SIMPLEX VIRUS, INFLUENZA, OTHERS.

In Application segment, HIV segment has highest cagr growth of 3.71%.

Based on the Region, the Acyclovir analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 3.71%.

Based on the region, the Acyclovir analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include AGIO PHARMACEUTICALS LIMITED, SYNMEDIC LABORATORIES, ZEE LABORATORIES LTD, CIPLA INC., BHAVISHYA PHARMACEUTICALS PVT LTD, GEO PHARMA PVT LTD, FINECURE PHARMACEUTICALS LTD, NOVUS LIFE SCIENCES PVT LTD _, TALENT LABORATORIES, ADLEY FORMULATION and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type Of Virus

Introduction

In 2021, HERPES SIMPLEX VIRUS TYPE I (HSV-1) segment has the highest revenue of US $1.16 billion and is expected to grow at CAGR of 3.71% by 2027 HERPES SIMPLEX VIRUS TYPE I (HSV-1) segment has highest cagr growth of 3.71%.

HERPES SIMPLEX VIRUS TYPE I (HSV-1)

HERPES SIMPLEX VIRUS TYPE I (HSV-1) segment was valued at US $1.07 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $1.49 billion by 2027. HERPES SIMPLEX VIRUS TYPE I (HSV-1) segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.32 billion opportunity in 2027 over 2021.

HERPES SIMPLEX VIRUS TYPE II (HSV-2)

HERPES SIMPLEX VIRUS TYPE II (HSV-2) segment was valued at US $0.63 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.88 billion by 2027. HERPES SIMPLEX VIRUS TYPE II (HSV-2) segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

VARICELLA ZOSTER VIRUS (VZV)

VARICELLA ZOSTER VIRUS (VZV) segment was valued at US $0.32 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.45 billion by 2027. VARICELLA ZOSTER VIRUS (VZV) segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.

EPSTEIN-BARR VIRUS (EBV)

EPSTEIN-BARR VIRUS (EBV) segment was valued at US $0.15 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.20 billion by 2027. EPSTEIN-BARR VIRUS (EBV) segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.

CYTOMEGALOVIRUS (CMV)

CYTOMEGALOVIRUS (CMV) segment was valued at US $0.04 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.05 billion by 2027. CYTOMEGALOVIRUS (CMV) segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Mechanism Of Action

Introduction

In 2021, NUCLEOTIDE POLYMERASE INHIBITORS segment has the highest revenue of US $1.36 billion and is expected to grow at CAGR of 3.71% by 2027 NUCLEOTIDE POLYMERASE INHIBITORS segment has highest cagr growth of 3.71%.

NUCLEOTIDE POLYMERASE INHIBITORS

NUCLEOTIDE POLYMERASE INHIBITORS segment was valued at US $1.26 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $1.75 billion by 2027. NUCLEOTIDE POLYMERASE INHIBITORS segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.38 billion opportunity in 2027 over 2021.

REVERSE TRANSCRIPTASE INHIBITORS

REVERSE TRANSCRIPTASE INHIBITORS segment was valued at US $0.61 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.85 billion by 2027. REVERSE TRANSCRIPTASE INHIBITORS segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

PROTEASE INHIBITORS

PROTEASE INHIBITORS segment was valued at US $0.31 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.44 billion by 2027. PROTEASE INHIBITORS segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $0.02 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.03 billion by 2027. OTHERS segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, HIV segment has the highest revenue of US $1.02 billion and is expected to grow at CAGR of 3.71% by 2027 HIV segment has highest cagr growth of 3.71%.

HIV

HIV segment was valued at US $0.94 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $1.31 billion by 2027. HIV segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.28 billion opportunity in 2027 over 2021.

HEPATITIS

HEPATITIS segment was valued at US $0.64 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.89 billion by 2027. HEPATITIS segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

HERPES SIMPLEX VIRUS

HERPES SIMPLEX VIRUS segment was valued at US $0.44 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.62 billion by 2027. HERPES SIMPLEX VIRUS segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.13 billion opportunity in 2027 over 2021.

INFLUENZA

INFLUENZA segment was valued at US $0.18 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.24 billion by 2027. INFLUENZA segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.05 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $0.00 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.01 billion by 2027. OTHERS segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.00 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $1.33 billion and is expected to grow at CAGR of 3.71% by 2027 EUROPE segment has highest cagr growth of 3.71%.

EUROPE

EUROPE segment was valued at US $1.23 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $1.70 billion by 2027. EUROPE segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.37 billion opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $0.90 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $1.24 billion by 2027. ASIA-PACIFIC segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.27 billion opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $0.09 billion in 2019 and is projected to grow at 3.71% CAGR over the forecast period to reach US $0.12 billion by 2027. LAMEA segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.